• Skip to main content
  • Skip to primary sidebar

JP Cornerstone

Just another Cornerstone Accelerator site

  • JP Cornerstone
  • About
    • About JP Cornerstone
    • Code of Ethics
    • Professional Practice Guidelines
    • External Privacy Notice
  • Offices
    • Stockholm
    • Helsinki
    • Oslo
    • Copenhagen
  • Services
    • Executive Search
    • Board Search
    • Leadership Consulting
    • Interim Management
    • JPC Selection
  • Insights
  • News
  • Contact

China Steps Up Control of Pharma Market

February 28, 2019 by Cornerstone International Group Leave a Comment

2019 is now really starting in China, with the beginning of the Year of the Pig. Everybody in the China pharma market is focusing on how the new central purchasing pilot will be deployed in the coming months.

At first glance it looks familiar, with convergence with known international practices: strengthening of bidding rules, phasing out of off-patent products, shortening of supply chain etc. Some see the changes as an “extension” of the older bidding system which is aggregating a number of regions (the name of the campaign is misleading: “7 provinces plus 4 cities”). The key is not here. In fact, deep price cuts are expected for a committed volume of products. It is a change of paradigm.

Reshaping Admin

In a typical way, the Authorities have started by reshaping the administrative structure in 2018 with a new leadership and reaching higher in the political hierarchy. Decision-making goes up to the Prime Minister.

At operational level, a new organization is also in place in order to integrate the whole “drug policy”. The new administration integrates medical insurance and pricing under one roof and is managed by a former vice minister of Finance. Even more important, they have decided a new approach (silu): “combination of market and plan”. The products delivered at hospital and reimbursed are considered now as under the direct management of the State and its plan. They have started with oncology which has imported products and the most expensive.

Volume Commitments

There will be commitment of volume purchased by the hospitals. It is the first time that this would be done at the level of province and above. The question will be the quality of the forecast and its consequences.

What will happen when numbers are not met? How to ensure supply if forecast is too low? How to compensate companies if price has been slashed but volume is not reached? How will the Authorities ensure that hospitals strictly implement the policy? There is currently a lot of contradictory news, such as whether the hospitals would keep the right to have a second round of negotiation procurement when they are grouped together.

More than a tendering system

The vision behind this scheme is far more than a new tendering system. It is in fact an integrated way to manage the use and supply of drugs in hospitals. The State is increasing control within the hospitals.

The new system is not limited to purchasing, but also includes prescription and operations in general. Directors of hospitals are no longer the highest authority in the hospitals and final decision-making is done by the Party Secretary.  Often, he or she is a former Director and knows his business, but the nature of the decision making within hospitals is changing and reverting to the past.

The behavior of doctors is also more controlled with guidelines that dictate the prescription of purchased products for at least 70% of their activity. The implementation will be strongly facilitated by the remarkable IT infrastructure developed in China in recent years.

Bottom line. We can foresee three major consequences if the current policies are fully implemented.

1. Impact on Patient Choice

First and most important, patient choice is at stake. Recently, the Authorities have very rightfully standardized procedures, bringing much needed rationalization. This work is not yet finished. But at same time the clinical reality should prevail, and Patients and Doctors need alternative therapeutic solutions. They should be given the choice to adapt their clinical strategy.

2. New Business Models

All companies will need to adjust their business model and P&L to a lower margin. Will international manufacturers still be able to promote innovation in big way? Will local manufacturers be able to raise quality if they have no incentive to do so? The slow-down of the Generic Quality Consistency Evaluation program has disappointed numerous local companies. Distributors too will have to make choices and focus on short-string supply or promote on behalf of the manufacturer.

Maybe most worrying, local start-ups are seeing their business plan and assumptions collapsing. Recent IPOs are almost all trading below their introductory price, in part because there was a bubble but also because investors now understand that pricing assumptions for new products are being slashed. Innovation – both local and international — requires reward.

One consequence of the impact on business models will be a reduction in the number of Medical Representatives employed for primary care products. This will limit the valuable education work that takes place on how to use primary care drugs to maximize healthcare outcomes and improve Chinese Patient Health.

Medical Representatives are major actors in organizing medical education events to share best practices among the healthcare community, creating educational bridges between tier 2/1 hospitals and tier 3 or even county hospital. Reducing their presence might go against one of the goals of the government to improve healthcare across all the hospitals.

3. Access to Talent

Finally, from the talent angle, we see that Market Access has now become the core requirement critical to navigating the policies at both the national level but also at the hospital level to follow detailed deployment. Demand is huge for talent in quality (address the challenges of the new policies and more sophisticated requirements) and at same time in quantity as access is needed at each province/city/hospital level. It is another hot recruitment and development area!

Filed Under: Cornerstone Blog

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Recent Posts

  • Cornerstone International Group Continues to Expand With Latest Addition: Cornerstone Montreal
  • Walter Baker Joins IERG Board of Directors
  • How Digital Transformation Is Reshaping the Pharma Industry
  • PRESS RELEASE: Cornerstone Kansas City Expands Midwest Market
  • PRESS RELEASE: Cornerstone International Group Launches New Logo 

Recent Comments

    Archives

    • May 2023
    • March 2023
    • February 2023
    • January 2023
    • December 2022
    • November 2022
    • August 2022
    • July 2022
    • June 2022
    • March 2022
    • February 2022
    • January 2022
    • December 2021
    • November 2021
    • October 2021
    • September 2021
    • August 2021
    • July 2021
    • June 2021
    • May 2021
    • April 2021
    • March 2021
    • February 2021
    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • February 2018
    • February 2017
    • January 2017
    • July 2016
    • April 2016
    • March 2016
    • February 2016
    • October 2015
    • April 2015
    • March 2015
    • October 2014
    • June 2014
    • April 2014
    • March 2014
    • February 2014
    • December 2013
    • August 2013
    • May 2013
    • April 2013
    • October 2012
    • September 2012
    • August 2012
    • May 2012
    • March 2012
    • January 2012
    • December 2011
    • November 2011
    • October 2011
    • September 2011
    • July 2011
    • May 2011
    • March 2011
    • January 2011
    • December 2010
    • August 2010
    • June 2010
    • May 2010
    • April 2010
    • March 2010
    • February 2010
    • January 2010
    • December 2009
    • November 2009
    • October 2009
    • September 2009
    • August 2009
    • July 2009
    • June 2009
    • May 2009
    • April 2009
    • March 2009
    • February 2009
    • January 2009
    • December 2008
    • November 2008
    • October 2008
    • September 2008
    • August 2008
    • July 2008
    • June 2008
    • April 2008
    • March 2008
    • February 2008
    • January 2008
    • December 2007
    • September 2007
    • August 2007
    • June 2007
    • April 2007
    • December 2006
    • November 2006
    • September 2006
    • August 2006
    • July 2006
    • June 2006
    • March 2006
    • February 2006
    • January 2006
    • November 2005
    • October 2005
    • September 2005
    • August 2005
    • July 2005
    • June 2005
    • May 2005
    • April 2005
    • March 2005
    • February 2005
    • January 2005
    • December 2004
    • November 2004
    • October 2004
    • September 2004
    • August 2004
    • July 2004
    • June 2004
    • May 2004
    • April 2004
    • March 2004
    • February 2004
    • January 2004
    • December 2003
    • November 2003
    • October 2003
    • September 2003
    • August 2003
    • July 2003
    • June 2003
    • May 2003
    • April 2003
    • March 2003
    • February 2003
    • January 2003
    • December 2002
    • November 2002

    Categories

    • Cornerstone Blog
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Copyright © 2023 · JP Cornerstone · Sitemap

    Website Development by LimeCuda